Klotho Neurosciences, Inc. (KLTO) Financial Ratios
4 years of historical data (2021–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
6.19
↓-21% vs avg
5yr avg: 7.88
30Y Low7.9·High7.9
ROE
↓
-700.1%
↑-197% vs avg
5yr avg: -235.8%
30Y Low-108%·High-54%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KLTO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Klotho Neurosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $7M | $9M | — | — | — |
| Enterprise Value | $8M | $10M | — | — | — |
| P/E Ratio → | -1.19 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 6.19 | 7.88 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KLTO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
KLTO Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -700.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -700.1% | -700.1% | -80.8% | -54.3% | -108.1% |
| ROA | -264.5% | -264.5% | -29.9% | -33.4% | -106.5% |
| ROIC | -242.3% | -242.3% | -21.1% | -27.1% | — |
| ROCE | -622.0% | -622.0% | -72.1% | -52.1% | -108.1% |
KLTO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $208012 ($271753 total debt minus $63741 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.23 | 2.57 | 1.14 | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | 0.18 | 2.56 | 1.08 | -0.29 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -15.54 | -15.54 | -8.28 | -23.57 | — |
KLTO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.13x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.24x to 0.13x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 0.13 | 0.13 | 0.00 | 0.24 | 20.12 |
| Quick Ratio | 0.13 | 0.13 | 0.00 | 0.24 | 20.12 |
| Cash Ratio | 0.05 | 0.05 | 0.00 | 0.06 | 19.88 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
KLTO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Klotho Neurosciences, Inc. returns 1.6% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 1.6% | 1.3% | — | — | — |
| Total Shareholder Yield | 1.6% | 1.3% | — | — | — |
| Shares Outstanding | — | $19M | $1.0B | $1.0B | $1.0B |
Peer Comparison
Compare KLTO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KLTOYou | $7M | -1.2 | — | — | — | — | -700.1% | -242.3% | — |
 SAVA | $64M | -2.5 | — | — | — | — | -17.2% | -634.1% | — |
 NRXP | $66M | -2.9 | — | — | 58.8% | -1324.4% | — | — | — |
 ACIU | $235M | -2.6 | — | — | 100.0% | -1927.3% | -89.6% | -99.2% | — |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 ATHA | $17M | -0.2 | — | — | — | — | -290.8% | — | — |
 BIIB | $30B | 22.7 | 11.9 | 14.4 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 ESPR | $655M | -28.6 | 17.1 | — | 67.9% | 15.0% | — | 66.5% | 9.1 |
 AVXL | $232M | -4.6 | — | — | — | — | -43.1% | — | — |
 ANVS | $35M | -1.3 | — | — | — | — | -220.6% | — | — |
 CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
What if you invested $1,000 in KLTO 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in KLTO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KLTO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKLTO vs SAVA — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Cassava Sciences, Inc..
Compare NowKLTO — Frequently Asked Questions
Quick answers to the most common questions about buying KLTO stock.
What is Klotho Neurosciences, Inc.'s P/E ratio?
Klotho Neurosciences, Inc.'s current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
What is Klotho Neurosciences, Inc.'s ROE?
Klotho Neurosciences, Inc.'s return on equity (ROE) is -700.1%. The historical average is -81.0%.
Is KLTO stock overvalued?
Based on historical data, Klotho Neurosciences, Inc. is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.